AAIC 2023 - Alzheimer's Association International Conference®

Posters 

Monday, July 17, 8:45 AM - 4:15 PM CEST

• P2-258 Fully automated ApoE4 assay in plasma and the estimation of the APOE polymorphism (Yuri Tatsushi, Fujirebio Europe, Gent, Belgium) 
• P2-902 Update to the Comparative Analytical Performance of Plasma Aβ Assays and their Relationship to Amyloid PET (FNIH, USA)
• P2-943 Concordance between APOE genotyping and proteotyping using the novel Lumipulse^® G Pan-ApoE and Lumipulse^® G ApoE4 RUO assays (Ina Vandenbroucke, Fujirebio Europe, Gent, Belgium)

Tuesday, July 18, 8:45 AM - 4:15 PM CEST

• P3-207 Comparison of the diagnostic performance of blood-based biomarkers using two distinct commercially-available assays in a prospective memory clinic cohort (Jordi Sarto, H Clinic, Barcelona, Spain) 
• P3-214 Fully Automated Lumipulse^® Plasma Amyloid and phosphorylated Tau assays for Progression to Alzheimer’s disease in Mild Cognitive Impairment patients (Anuschka da Silva-Spinola, CHU Coimbra, Portugal) 
• P3-251 High Precision β-Amyloid 1-40, β-Amyloid 1-42, and Ptau181 Plasma Assay Performance in NCRAD Biomarker Assay Laboratory (Kristen Russ, Indiana University, USA)
• P3-277 Preliminary performance of the Lumipulse^® G pTau 217 Plasma prototype assay on plasma samples (Manu Vandijck, Fujirebio Europe, Gent, Belgium)
• P3-283 Comparison of plasma Aβ42, Aβ40, and p-tau181 assessed on two different platforms with CSF AD biomarkers (Michelle Mielke, Wake Forest University, USA) 

Wednesday, July 19, 8:45 AM - 4:15 PM CEST

• P4-222 Automatic assessment of classical Alzheimer’s disease biomarkers in paired cerebrospinal fluid and plasma samples (Andrea Toja, University of Perugia, Italy) 

  
Oral presentations

Sunday, July 16, 8:00 AM – 8:45 AM CEST

• 1-04-DEV LEADS: Scientific advances in Sporadic Early-Onset Alzheimer’s Disease: Exploring the Utility of Biofluid-Based Biomarkers in Early-Onset Alzheimer’s Disease (Jeff Dage, Indiana University, USA)

Thursday, July 20, 11:30 AM - 12:45 PM CEST

• 5-15-FRS-C The prognostic utility of blood-based biomarkers: Diagnostic performance and clinical applicability of plasma pTau181 to predict dementia risk in a large real-world cohort of a memory clinic (Amanda Cano, Fundacio ACE, Barcelona, Spain)

Also, be sure not to miss the posters presented by colleagues from our product developments teams at ADx NeuroSciences and their collaborators, see an overview here!